erlotinib hydrochloride has been researched along with curcumin in 4 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (curcumin) | Trials (curcumin) | Recent Studies (post-2010) (curcumin) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 16,336 | 593 | 12,705 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Izumi, Y; Nomori, H; Yamamoto, J; Yamauchi, Y | 1 |
Fan, X; Jiang, L; Li, S; Liu, Z; Wu, X; Zhao, H; Zhu, F | 1 |
Cheng, C; Hu, X; Shi, S; Sui, B; Wang, M; Xu, P | 1 |
Bagherian, A; Masoudian, N; Mirzaei, H; Roudi, B | 1 |
4 other study(ies) available for erlotinib hydrochloride and curcumin
Article | Year |
---|---|
Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Erlotinib Hydrochloride; Humans; I-kappa B Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference | 2014 |
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Random Allocation; Survivin; Xenograft Model Antitumor Assays | 2013 |
Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Curcumin; Erlotinib Hydrochloride; Mice; Nanoparticles; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Curcumin; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Micelles; Nanostructures | 2021 |